Catalyst Pharmaceuticals
CPRXCPRX · Stock Price
Historical price data
Overview
Catalyst Pharmaceuticals has successfully transitioned from a development-stage entity to a profitable commercial organization focused on rare neuromuscular and neurological diseases. Its strategy centers on acquiring or in-licensing late-stage/commercial assets, maximizing lifecycle value, and maintaining an intense patient-first operational culture. This approach has yielded a marketed portfolio, a growing pipeline, and recognition as a top small-cap company, positioning it for continued growth in specialized therapeutic areas.
Technology Platform
A specialized commercial and development platform for rare disease therapies, focusing on late-stage asset acquisition, regulatory strategy, targeted commercialization, and comprehensive patient support, rather than a proprietary drug discovery technology.
Pipeline
14| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Amifampridine Phosphate + Placebo | Lambert Eaton Myasthenic Syndrome | Phase 3 | |
| amifampridine phosphate + Placebo | Myasthenic Syndromes, Congenital | Phase 3 | |
| Amifampridine Phosphate + Placebo Oral Tablet | Lambert-Eaton Myasthenic Syndrome | Phase 3 | |
| Amifampridine Phosphate + Placebo Oral Tablet | Myasthenia Gravis, Generalized | Phase 3 | |
| Amifampridine Phosphate | Myasthenia Gravis, MuSK | Phase 3 |
FDA Approved Drugs
2Opportunities
Risk Factors
Competitive Landscape
AGAMREE competes with standard corticosteroids in DMD, differentiating on safety profile. FIRDAPSE competes directly with generic amifampridine in LEMS. Catalyst's primary competitive advantage is its integrated rare disease commercial platform and patient support ecosystem, which are difficult for generic firms or large pharma to replicate in niche markets.